# Helus Pharma Discusses Mental Health Drug Strategy

> Helus Pharma reveals Phase 3 plans for mental health drugs targeting serotonin pathways.
- Title: Helus Pharma Discusses Mental Health Drug Strategy | Shortify
- Summary: Helus Pharma reveals Phase 3 plans for mental health drugs targeting serotonin pathways. Helus Pharma announced Phase 3 clinical trials for novel…
- Keywords: helus pharma, serotonergic agonists, phase 3 trials, mental health, clinical pipeline, serotonin, money, business, Helus, Pharma, Discusses, Mental
- Source: Seekingalpha — https://seekingalpha.com/article/4955978-helus-pharma-inc-help-discusses-clinical-pipeline-and-phase-3-strategies-for-novel
- Author: SA Transcripts
- Published: 2026-10-21T21:43:59+00:00
- Read time: 1 min
- Topics: helus pharma, serotonergic agonists, phase 3 trials, mental health, clinical pipeline, serotonin, money, business
## Helus Pharma CEO
Helus Pharma CEO Michael Halstead discussed clinical pipeline and Phase 3 strategies for novel serotonergic agonists in mental health.
## Conference Participants
The call included CEO Michael Halstead, Chief Medical Officer Amir Inamdar, and Senior VP of Medical Affairs Ken Kramer.
## Forward-Looking Statements
The company warned that forward-looking statements may differ materially from actual results and are subject to risks.
## Key takeaway

Helus Pharma announced Phase 3 clinical trials for novel serotonergic agonists to treat mental health conditions.